相关实验视频

Updated: May 28, 2025

Quantitative Measurement of γ-Secretase-mediated Amyloid Precursor Protein and Notch Cleavage in Cell-based Luciferase Reporter Assay Platforms

Quantitative Measurement of γ-Secretase-mediated Amyloid Precursor Protein and Notch Cleavage in Cell-based Luciferase Reporter Assay Platforms

Published on: January 25, 2018

阿尔茨海默氏症突变性γ-分泌酶复合体会阻碍粉样蛋白β-的产生

Parnian Arafi¹, Sujan Devkota¹, Emily Williams²

¹Department of Medicinal Chemistry, University of Kansas, Lawrence, United States.

|February 11, 2025

概括

亲属性阿尔茨海默氏病突变在 presenilin-1 (PSEN1) 阻碍了马分泌酶复合体. 这种停滞,而不是粉样β的产生,似乎在阿尔茨海默病模型中引发了突触退化.

科学领域:

神经科学是一个神经科学.
分子生物学分子生物学
遗传学遗传学是一个

背景情况:

家庭性阿尔茨海默病 (FAD) 与粉样蛋白前体蛋白 (APP) 和 presenilin-1 (PSEN1) 的突变有关.
含有PSEN1的复合物马分泌酶分裂APP产生粉样蛋白-β (Aβ) ,这是粉样蛋白假设的核心.
玛分泌酶的APP蛋白解是一种过程性修剪机制,而不是单一的裂变事件.

研究的目的:

为了研究6个额外的PSEN1 FAD突变对玛分泌酶基质加工的影响.
为了确定FAD突变是否导致特定蛋白质分解步骤的缺陷或阻断酶复合体.
评估停滞的酶复合体与Aβ生产在FAD病变发生过程中的作用.

主要方法:

对六种PSEN1 FAD突变体的玛分泌酶对APP基质的所有蛋白质分解事件的定量分析.
光终身成像显微镜 (FLIM) 在完整的细胞中可视化酶基质/中间体复合体.
在C99丰富和Aβ丰富的细胞区域中处理缺陷的比较.

主要成果:

分析的所有6种PSEN1 FAD突变都导致多个玛分泌酶处理步骤的缺陷.
五种突变体在内蛋白解和修剪方面表现出缺陷,而F386S仅在修剪方面有缺陷.
在所有六种突变体中,FLIM揭示了停滞的马分泌酶基质/中间体复合体,其中F386S停滞局限于Aβ丰富的区域.

结论:

在PSEN1中的FAD突变导致停滞和稳定的玛分泌酶-基质/中间体复合体.
马分泌酶处理途径的停滞,而不是Aβ生产,是FAD的可能致病触发因素.
这些发现挑战了传统的粉样蛋白假设,因为它暗示了酶复合体对积的功能障碍.

关键词:

生物化学生物化学化学生物学化学生物学光显微镜的光显微镜.质谱测量质谱测量质谱测量质谱测量质量测量质谱测量质量测量质量测量质量测量质量测量质量测量质量测量质量测量质量测量质量测量质量测量质量测量质量测量质量测量质量测量质量测量质量测量质量测量质量测量质量测量没有,没有,没有.蛋白质溶解过程中的蛋白质溶解.这是一个秘密,一个秘密,一个秘密.

更多相关视频

Visualization of Amyloid β Deposits in the Human Brain with Matrix-assisted Laser Desorption/Ionization Imaging Mass Spectrometry

Visualization of Amyloid β Deposits in the Human Brain with Matrix-assisted Laser Desorption/Ionization Imaging Mass Spectrometry

Published on: March 7, 2019

Imaging the Intracellular Trafficking of APP with Photoactivatable GFP

Imaging the Intracellular Trafficking of APP with Photoactivatable GFP

Published on: October 17, 2015

相关概念视频

Amyloid Fibrils

Amyloid Fibrils

Amyloid fibrils are aggregates of misfolded proteins. Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils.
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...

Alzheimer's Disease: Overview

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...

Alzheimer's Disease: Treatment

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...